GRADE 2 FOLLICULAR LYMPHOMA
Clinical trials for GRADE 2 FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new GRADE 2 FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for GRADE 2 FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail tested for aggressive lymphomas
Disease control OngoingThis early-stage study is testing a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in patients whose B-cell non-Hodgkin lymphoma has come back or hasn't responded to previous treatments. The main goal is to find the safest and most effective dose of the dru…
Matched conditions: GRADE 2 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated Apr 01, 2026 23:11 UTC
-
New drug combos tested for Tough-to-Treat blood cancer
Disease control OngoingThis study is testing several new drug combinations to see which works best for adults with follicular lymphoma, a type of blood cancer, that has come back early or did not respond to their first round of treatment. Participants are assigned to receive one of three different trea…
Matched conditions: GRADE 2 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Double-Punch combo trial aims to boost Cancer-Killing power
Disease control OngoingThis study is testing whether adding a pill called acalabrutinib makes a powerful cell therapy (CAR-T) work better and safer for people with certain aggressive B-cell lymphomas. The trial enrolled 23 adults to see if the combination is safe and can help control the cancer. Resear…
Matched conditions: GRADE 2 FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
New drug duo aims to control Slow-Growing blood cancer without chemotherapy
Disease control OngoingThis study is testing how well two targeted drugs, obinutuzumab and ibrutinib, work together as the first treatment for people with certain slow-growing types of non-Hodgkin's lymphoma. The goal is to control the cancer by stopping cancer cells from growing and spreading, potenti…
Matched conditions: GRADE 2 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC